Tag Archives: AstraZeneca Expands Rare Disease Portfolio with EU Approval of Koselugo for Adults with NF1 Tumours

European Commission Authorises AstraZeneca’s Koselugo for Adult Neurofibromatosis Type 1 Patients After Landmark KOMET Trial

Posted on 29, October 2025 by EuropaWire PR Editors

(IN BRIEF) AstraZeneca’s Alexion has secured European Commission approval for Koselugo (selumetinib), the first targeted therapy available to adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The approval is based on the KOMET Phase III trial, … Read the full press release →

Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom

Tagged adult NF1 treatment, Alexion, American Society of Clinical Oncology, APHP, ASCO 2025, AstraZeneca, AstraZeneca Expands Rare Disease Portfolio with EU Approval of Koselugo for Adults with NF1 Tumours, European Commission approval, European Union, Henri Mondor Hospital, Japan approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, Paris East University, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease therapy, selumetinib, The Lancet, tumour response rate, UPEC